Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Lung Neoplasms 2Thymoma 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Metastatic Solid Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Kidney Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 2Celecoxib 2pembrolizumab 1olaparib 1fludarabine 1entinostat 1bosutinib 1Radiofrequency Ablation 1Psychiatric Rehabilitation 1Pemetrexed 1Leucovorin 1Imatinib Mesylate 1Fentanyl 1FANG vaccine 1Early Intervention, Educational 1Doxepin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thymoma × FANG vaccine × Other solid neoplasm × Clear all
NCT01258868 2019-12-03

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
44 enrolled
GastrointestinalOther solid neoplasmThoracic

Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡